---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-21-043064"
form_type: "8-K"
ticker: "BDSX"
cik: "0001439725"
company_name: "BIODESIX INC"
filed_at: "2021-08-10T23:59:59+00:00"
generated_at: "2026-06-29T16:31:21.293279+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.72
calibrated_materiality_score: 0.72
confidence: "high"
source: SEC EDGAR
---

# Biodesix Q2 total revenue $11.9M (+180%), core lung diagnostics $4.8M (+109%); NGS test launch accelerated to Q1 2022

## Summary
- Total revenue $11.9M (+180% YoY); core lung diagnostic revenue $4.8M (+109%).
- COVID-19 testing revenue $6.1M (+345%) but declining sequentially; net loss $11.4M (+38%).
- Gross profit $4.8M (40% margin); operating expenses $15.4M (+93%) due to sales force buildout.
- Nodify XL2 milestone triggers $37M obligation payable over six quarterly installments starting Jan 2022.
- Accelerated launch of 72-hour liquid NGS test to Q1 2022; cash $56.3M; expects $3.1M PPP loan forgiveness.

## SEC filing metadata
- accession: 0001564590-21-043064
- form_type: 8-K
- ticker: BDSX
- cik: 0001439725
- company_name: BIODESIX INC
- filed_at: 2021-08-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.72
- calibrated_materiality_score: 0.72
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1439725/000156459021043064/0001564590-21-043064-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1439725/000156459021043064/bdsx-8k_20210810.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-21-043064
- JSON: https://secwatch.observer/filing/0001564590-21-043064.json
- Plain text: https://secwatch.observer/filing/0001564590-21-043064.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.